Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03032523
Other study ID # 36668
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2016
Est. completion date April 1, 2018

Study information

Verified date July 2019
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypoglycemia is the most common metabolic problem faced after birth. The investigators will be studying the utility of using a continuous glucose monitoring(CGM) system to more closely monitor low blood sugars in newborns. The investigators will evaluate the number of hypoglycemic events detected using CGM and compare it to those detected using current standard of care screening methods.


Description:

A CGM will be subcutaneously inserted by trained staff on a healthy area of skin and will be calibrated according to the manufacturer's instructions. Blood glucose measurements will be taken using a blinded study glucometer to calibrate the device. Calibration by trained study staff will take place about every 12 hours. Sensor insertion sites will be monitored for infection throughout the course of the study by nursing and clinical staff or by trained study staff on an as needed basis. At the conclusion of the study, the CGM will be removed and assessed for signs of infection. Study duration will be up to 7 days while the patient is admitted to the hospital.

Participants will be randomized into 2 groups. The control group will have a blinded CGM in place for the duration of the study. The remote monitoring group will be blinded to clinical staff. This group will have a CGM connected to an iPod that sends continuous glucose data to the study phone and will be monitored 24/7 by study staff. If a blood sugar level of <46 mg/dl is detected, the infant will first be evaluated for positioning that could be causing a falsely low value. If the infant is re-positioned and CGM continues to show a blood sugar level of <46 mg/dl, study staff will prompt the nurse taking care of the patient to obtain a capillary glucose value to verify the low blood sugar and treat it as deemed appropriate by the clinical team.

The investigators will evaluate the number of hypoglycemic events that occur in the blinded CGM group versus the number that occur in the remote monitoring group to assess if the CGM is able to more sensitively detect low blood sugars in infants than current hospital standard of care measures.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date April 1, 2018
Est. primary completion date April 1, 2018
Accepts healthy volunteers No
Gender All
Age group N/A to 7 Days
Eligibility Inclusion Criteria:

- Infants who are at least 34 weeks gestation that are born to mothers with gestational or pre-gestational diabetes and are admitted to LPCH are eligible for the study.

Exclusion Criteria:

- Infants <2,000 grams will be excluded from the study. Infants will also be excluded if they have an anomaly of the skin or subcutaneous tissue that would prevent proper adhesion, placement, and function of the sensor.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Standard of care glucose test
If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.

Locations

Country Name City State
United States Stanford University Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensor-detected Hypoglycemia Reported values in the table represent the cumulative number of hypoglycemic events detected by the sensor that were not detected by the hospital standard of care measures across all participants. up to 8 days
Secondary Sensitivity of the CGM to Detect Hypoglycemia. True positive rate. up to 7 days
Secondary Specificity of CGM to Detect Hypoglycemic Events True negative rate up to 7 days
See also
  Status Clinical Trial Phase
Completed NCT02583776 - Continuous Glucose Monitoring and Preterm Infants Phase 4
Not yet recruiting NCT05977972 - Pattern of Metabolic Causes of Neonatal Hypoglycemia
Recruiting NCT04458649 - Continuous Glucose Monitoring in Infants
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Completed NCT03726697 - Effect of Tahneek on Hypoglycemia in Newborn Infants N/A
Terminated NCT04085978 - Effects of a Hypoglycemia Protocol With Glucose Gel on Neonatal Intensive Care Unit (NICU) Admission
Terminated NCT05647798 - Intrapartum Glycemic Control in GDMA2 N/A
Not yet recruiting NCT04811612 - Comparing Heel Stick Glucoses in Neonates N/A
Not yet recruiting NCT02648555 - A Lifestyle Intervention to Improve in Vitro Fertilization Results N/A
Recruiting NCT06373432 - Frequency of Glucose Monitoring in Labor N/A
Completed NCT04030312 - Effectiveness of Donor Human Milk Supplementation for the Treatment of Hypoglycemia in the Breastfed Infant N/A
Completed NCT03076775 - Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study N/A
Completed NCT05022433 - Comparison of the Shukla and UN-1 Formulae in the Placement of the Umbilical Venous Catheter Among Neonates
Recruiting NCT00332449 - Early Breast Feeding and Glucose Levels in High Risk Newborns N/A
Not yet recruiting NCT04869709 - Late Preterm Corticosteroids and Neonatal Hypoglycemia Phase 4
Completed NCT02523222 - Prophylactic Dextrose Gel for Newborns at High-risk for Hypoglycemia N/A
Recruiting NCT04875624 - Neurodevelopment of Hypoglycemic Neonates
Completed NCT02605369 - SURVIVAL PLUSS: Increasing Capacity for Mama-baby Survival in Post-conflict Uganda and South Sudan N/A
Withdrawn NCT03738293 - Continuous Glucose Monitoring of Late Preterm Birth After Corticosteroids
Recruiting NCT04386005 - Continuous Glucose Monitoring in At-Risk Newborns N/A